Ascendis Pharma A/S ADR [ASND] stock is trading at $167.47, down -1.74%. An important factor to consider is whether the stock is rising or falling in short-term value. The ASND shares have gain 4.38% over the last week, with a monthly amount glided 10.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on April 16, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $205. Previously, UBS started tracking the stock with Buy rating on January 07, 2025, and set its price target to $196. On September 05, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $180 on the stock. TD Cowen upgraded its rating to a Buy and increased its price target to $175 on June 25, 2024. Stifel initiated its recommendation with a Buy and recommended $200 as its price target on May 31, 2024. Jefferies started tracking with a Buy rating for this stock on December 20, 2023, and assigned it a price target of $150.
Ascendis Pharma A/S ADR [ASND] stock has fluctuated between $111.09 and $171.34 over the past year. Currently, Wall Street analysts expect the stock to reach $180 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $167.47 at the most recent close of the market. An investor can expect a potential return of 7.48% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 391.88M for the trailing twelve months, which represents a growth of 25.27%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -1.03%, and Net Profit Margin reading is -1.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 1.98 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -8.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 163.66 points at the first support level, and at 159.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 172.14, and for the 2nd resistance point, it is at 176.81.
Ratios To Look Out For
For context, Ascendis Pharma A/S ADR’s Current Ratio is 1.17. On the other hand, the Quick Ratio is 0.84, and the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 25.57.
Transactions by insiders
Recent insider trading involved JENSEN MICHAEL WOLFF, Officer, that happened on Mar 07 ’25 when 4000.0 shares were purchased. Officer, JENSEN FLEMMING STEEN completed a deal on Mar 06 ’25 to buy 10000.0 shares. Meanwhile, Officer JENSEN MICHAEL WOLFF bought 1614.0 shares on Mar 06 ’25.
